Long-term Outcomes of Breast Cancer Patients After Wound Infiltration Analgesia
Postoperative Analgesia, Hand Strength, Health Related Quality of Life
About this trial
This is an interventional treatment trial for Postoperative Analgesia focused on measuring Acute Postoperative Pain, Breast Cancer, Postoperative analgesia, Patient-Controlled Analgesia, Levobupivacaine, Diclofenac, Hand Grip Strength, Quality of life, Treatment Outcome
Eligibility Criteria
Inclusion Criteria: Breast cancer patients whose disease requires axillary lymph node dissection who consented to participate in the study aged 30 - 75 The patient is able to understand all three methods of analgesia Patients can receive any of the study drugs Able to understand and complete questionnaires on quality of life and shoulder pain Exclusion Criteria: Age <30 years - >75 years Patients who refused to participate in the study (at any stage of the study) Patients who after histological analysis did not require axillary lymph node dissection Patients with known intolerance to study drugs Patients who unintentionally removed wound infiltration catheters. Patients who required surgical reintervention during the study period Patients having adverse reactions to any study drug.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Experimental
Experimental
Diclofenac
Levobupivacaine bolus analgesia
Levobupivacaine PCA group
All patients underwent quadrantectomy or mastectomy with axillary lymph node dissection. They received diclofenac 2 x 75 mg intravenously on the first day after surgery. During the 3 subsequent days, from day 2 to day 4 postoperatively patients were given 3 x 50 mg diclofenac tablets orally. The medicine was delivered by the nurse, and the patients drank tablets in front of her.
Group Levobupivacaine Bolus received 0.5 mg/kg 0.5% Levobupivacaine HCl every 8 h via wound catheter. The dose of levobupivacaine was prescribed by the doctor and the drug was delivered by the nurse.
Group Levobupivacaine patient-controlled analgesia (PCA) received 0.05 mg/kg 0.5% Levobupivacaine HCl continuously via wound catheter delivered by CADD - Legacy® PCA Pump. These patients were allowed to add a dose of 7.5 mg 0.5% levobupivacaine in case of pain by pressing the patient's button on the PCA pump, with a lock-out period of 4 hours.